Pharma stock falls 15% this year. Why Motilal Oswal has 'Buy' tag
Motilal Oswal believes the pharma company is well-placed to gain from the drug shortages in the US
Gland Pharma has a decent opportunity size for injectable drugs under shortages to drive near term growth. In the medium-term, its launch momentum, filing pace, upside from recently launched products in the US, and the new Enoxaparin contract is expected to drive 16% sales CAGR in its core markets over FY22-24, as per Motilal Oswal.
Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!Let’s get started